Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3147Neoplasms 2478Carcinoma, Non-Small-Cell Lung 1889Prostatic Neoplasms 1645Colorectal Neoplasms 1438Lung Neoplasms 1312Multiple Myeloma 940Neoplasm Metastasis 930Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 862Ovarian Neoplasms 815Melanoma 794Carcinoma, Hepatocellular 745Stomach Neoplasms 650Brain Neoplasms 643Recurrence 642Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 613Glioblastoma 575Lymphoma 551Uterine Cervical Neoplasms 549Triple Negative Breast Neoplasms 515Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 505Endometrial Neoplasms 467Hematologic Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 448Sarcoma 439Lymphoma, Non-Hodgkin 439

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Gland Diseases × 1 year × Clear all
NCT05370521 2025-10-09

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Spruce Biosciences

Phase 2 Terminated
27 enrolled 18 charts

Adrenal Gland Diseases, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡